Our library of drug research abstracts drawn from the medical literature is updated on a regular schedule, and you can be assured that new diprolene research articles will be listed here shortly after becoming available to us.
Related Sponsors
Medical research on diprolene
Chem Pharm Bull (Tokyo). 2008 May; 56(5): 663-7
Takegami S, Kitamura K, Funakoshi T, Kitade T
The partition coefficients (Kps) of six anti-inflammatory steroid drugs, dexamethasone (DMS), betamethasone (BMS), triamcinolone acetonide (TCLA), fluocinolone acetonide (FCLA), betamethasone 17,21-dipropionate (BMSDP), and clobetasole propionate (CBSP), for phosphatidylcholine (PC), and PC-cholesterol small unilamellar vesicles (SUVs) were determined by a second-derivative spectrophotometric method. The Kp values were obtained with a relative standard deviation of below 10% and the following order was observed: BMS< or =DMS
[Childhood actinic lichen planus (6 cases)]
Arch Pediatr. 2008 Feb; 15(2): 111-4
Dammak A, Masmoudi A, Boudaya S, Bouassida S, Marrekchi S, Turki H
INTRODUCTION: Actinic lichen planus (ALP) is a chronic and benign disease that affects young people of the Middle East and Maghreb countries. PURPOSE: To analyse clinical features and prognosis of ALP in children. PATIENTS AND METHODS: A retrospective, descriptive study of cases observed in the department of dermatology of Sfax hospital over a period of 11 years (1995-2005). RESULTS: Our patients were 5 boys and 1 girl. Mean age at diagnosis was 11 years. Onset was during the summer in 5 cases. The face was involved in 5 cases and the upper limb in 3 cases. The annular form was found in 5 cases, the pigmented melasma-like form in 1. Cheilitis was associated in 3 cases. Treatment consisted in photoprotection in all the patients. Antimalaria drugs were used in 4 patients and topical steroids in 2. Evolution was favourable in 5 cases. Disease relapsed in one child after treatment interruption. CONCLUSION: ALP can be seen during childhood. Ultraviolet rays are involved in pathogenesis. The annular form is predominant. Treatment is based on sun protection associated with antimalarials or topical steroids.
Eur J Dermatol. 2008 Jan-Feb; 18(1): 36-40
Pineau N, Bernerd F, Cavezza A, Dalko-Csiba M, Breton L
Severe structural changes, including deterioration of the mechanical properties of the dermis, occur during skin aging. It is well known that the degradation of the extracellular matrix contributes to the physical changes in aged skin. Whereas many studies have been devoted to age-related alterations of collagen fibrils, far less attention has been paid to another major family of extracellular matrix components, the glycosaminoglycans (GAGs) and proteoglycans (PGs). Heparan sulphate-proteoglycans, (HS-PGs), a subclass of the PG family that decreases during aging, regulate proliferation and proteolysis as well as matrix adhesion and assembly, and thus, may have important functions in skin. These PGs may represent important targets for dermo-cosmetology in fighting skin aging. The purpose of this study was to demonstrate the potential of a new C-xylopyranoside derivative (C-beta-D-xylopyranoside-2-hydroxy-propane simplified as C-Xyloside) to improve HS-PGs expression in human skin. In an organotypical model of corticosteroid atrophic human skin, characterized by a decrease of PGs expression, treatment with C-Xyloside improved expression of HS-PGs.
Arch Orthop Trauma Surg. 2007 Dec; 127(10): 885-8
Weksler N, Velan GJ, Semionov M, Gurevitch B, Klein M, Rozentsveig V, Rudich T
BACKGROUND CONTEXT: It is a common practice to the link low back pain with protruding disc even when neurological signs are absent. Because pain caused by sacroiliac joint dysfunction can mimic discogenic or radicular low back pain, we assumed that the diagnosis of sacroiliac joint dysfunction is frequently overlooked. PURPOSE: To assess the incidence of sacroiliac joint dysfunction in patients with low back pain and positive disc findings on CT scan or MRI, but without claudication or objective neurological deficits. METHODS: Fifty patients with low back pain and disc herniation, without claudication or neurological abnormalities such as decreased motor strength, sensory alterations or sphincter incontinence and with positive pain provocation tests for sacroiliac joint dysfunction were submitted to fluoroscopic diagnostic sacroiliac joint infiltration. RESULTS: The mean baseline VAS pain score was 7.8 +/- 1.77 (range 5-10). Thirty minutes after infiltration, the mean VAS score was 1.3 +/- 1.76 (median 0.000E+00 with an average deviation from median = 1.30) (P = 0.0002). Forty-six patients had a VAS score ranging from 0 to 3, 8 weeks after the fluoroscopic guided infiltration. There were no serious complications after treatment. An unanticipated motor block that required hospitalization was seen in four patients, lasting from 12 to 36 h. CONCLUSIONS: Sacroiliac joint dysfunction should be considered strongly in the differential diagnosis of low back pain in this group of patients.
Postzoster cutaneous pseudolymphoma in a patient with B-cell chronic lymphocytic leukaemia.
J Eur Acad Dermatol Venereol. 2007 Sep; 21(8): 1112-4
Moreira E, Lisboa C, Azevedo F, Príncipe F, Lima M
Curr Med Res Opin. 2007 Aug; 23(8): 1887-901
Bottomley JM, Auland ME, Morais J, Boyd G, Douglas WS
OBJECTIVES: To determine the cost-effectiveness of calcipotriol/betamethasone dipropionate (Dovobet) in the initial treatment of moderate severity plaque psoriasis vulgaris in Scotland. RESEARCH DESIGN AND METHODS: An economic model was developed to simulate the costs and benefits of the most commonly used topicals in the management of plaque psoriasis. This was informed by an indirect unadjusted comparison of the effectiveness data to determine the relative efficacy of commonly used topicals. The model estimated their impact on costs and utility gain over a 1-year period. We accounted for direct medical costs from a health payer perspective. The cost-utility analysis included pharmacy costs and costs of failure of topicals in primary care in terms of secondary-care referrals for phototherapy. Extensive sensitivity analyses were undertaken to address areas of uncertainty in the parameters of the model. RESULTS: Patients treated with the two-compound formulation (TCF) of calcipotriol and betamethasone dipropionate (BDP) experienced better control of their psoriasis. In our model, this translated into reduced costs, as patients were less likely to be referred for phototherapy, and increased quality adjusted life years (QALYs) relative to other commonly used topicals. The TCF was estimated to generate annual savings ranging from 96 to 276 pounds per patient per year compared to the other commonly used alternative topicals. With reduced costs and superior outcomes, the TCF 'dominated' these other treatments since the latter were associated with higher cost and lower utility or QALY gain. The model findings were not influenced by changes to a range of model input parameters within plausible limits. CONCLUSIONS: Use of the TCF in patients with plaque psoriasis represents excellent value for money by delivering savings to the National Health Service (NHS) in Scotland. Similar findings are predicted for the management of psoriasis patients elsewhere in the UK.
First case series on the use of calcipotriol-betamethasone dipropionate for morphoea.
Br J Dermatol. 2007 Sep; 157(3): 615-8
Dytoc MT, Kossintseva I, Ting PT
Presse Med. 2007 Sep; 36(9 Pt 1): 1207-8
Lortholary A, Cary-Ten Have Dallinga M, El Kouri C, Morineau N, Ramée JF
INTRODUCTION: Paclitaxel (Taxol) is a drug derived from the bark of the Pacific yew tree and is widely used in cancer treatment, especially for breast, ovarian, and lung cancers. It has not previously been reported to induce lupus. CASE: We report the case of a woman with ovarian cancer who developed paclitaxel-induced lupus on two occasions. Both times, the paclitaxel dramatically improved the ovarian cancer. DISCUSSION: The diagnosis of lupus was confirmed by the initial skin appearance, elevated levels of antinuclear antibodies, recurrence on reintroduction, and biopsy results. To our knowledge, it is the first case reported of paclitaxel-induced lupus.
Allergol Int. 2007 Jun; 56(2): 139-48
Yamamoto M, Haruna T, Yasui K, Takahashi H, Iduhara M, Takaki S, Deguchi M, Arimura A
BACKGROUND: Atopic dermatitis is a chronically relapsing inflammatory skin disease. Animal models induced by relevant allergens play a very important role in the elucidation of the disease. The patients with atopic dermatitis are highly sensitized with mite allergens such as Dermatophagoides farinae (Df). Therefore, in the present study, we tried to develop a novel model for atopic dermatitis by repeated application with Df extract ointment. METHODS: Df extract ointment was repeatedly applied to the back of NC/Nga mice together with barrier disruption. Atopic dermatitis-like skin lesions were evaluated by dermatitis scores, skin histology and immunological parameters. The effect of corticosteroid and calcineurin inhibitor was also examined. RESULTS: Repeated application of Df extract ointment caused rapid increase in dermatitis scores. Clinical (skin dryness, erythema, edema and erosion) and histological symptoms (dermal and epidermal thickening, hyperkeratosis, parakeratosis and inflammatory cell infiltration) in this model were very similar to those in human atopic dermatitis. Serum total and Df-specific IgE levels were elevated in this model compared with normal mice, and draining lymph node cells isolated from the mice that exhibited dermatitis produced significant amounts of interleukin-5, interleukin-13 and interferon-gamma after re-stimulation with Df. Furthermore, current first-line drugs for the treatment of human atopic dermatitis, corticosteroid and tacrolimus ointments, were effective against the clinical and histological symptoms in this model. CONCLUSIONS: These results suggest that the model we have established is useful for not only elucidating the pathogenesis of atopic dermatitis but also for evaluating therapeutic agents.
Advances in first-line topical therapies: the role of a 2-compound ointment for psoriasis vulgaris.
Cutis. 2007 Jan; 79(1 Suppl 2): 3-4
Lebwohl MG